Odronextamab in Low Tumor Volume Advanced FL (NCT07128641)
A Phase II Study of Odronextamab in Treatment Naïve Patients With Low Tumor Volume Advanced Stage Follicular Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab. The name of the study drug in this research study is: -Odronextamab (a type of monoclonal antibody)
Who can join: Review the eligibility criteria below.
Location: Beth Israel Deaconess Medical Center — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 667-9920
Email: gkeudell@bidmc.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Follicular Lymphoma
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas — New York, New York
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — Bethesda, Maryland
- Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma — Basking Ridge, New Jersey
- Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma — New York, New York
- Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma — Boston, Massachusetts
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Concord, California
Explore by condition: All Follicular Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.